Dataset opportunity
Encaplast — 监管记录数据集机会
Encaplast 持有的中等规模监管记录数据集，可用于监管 RAG 和合规性 Copilots。
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务市场 = 2024 年为 164 亿美元，复合年增长率为 8.8%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-10-26
ENCAPLAST: il packaging medicale cresce insieme al Distretto Biomedicale Mirandolese
distrettobiomedicale.it ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
部分
Legal
公司所有 — 许可干净
Buyer persona
RegTech 和合规性 AI 供应商
Encaplast 持有一个由其质量管理和工业控制系统生成的监管记录数据集，该数据集包含文本格式的业务记录、工业数据和监管申报文件。该数据集遵循严格的ISO 13485标准，提供高完整性的结构化文档，非常适合监管 RAG用例，能够精确回答复杂的合规性问题。
全球监管事务市场在2024 年的价值为 164 亿美元，预计将以8.8% 的复合年增长率增长。尽管由于数据存储在本地化系统中存在访问复杂性，但其价值巨大。高标准的文档记录使这个有价值的数据集成为任何寻求在复杂的医疗器械领域实现合规性自动化的 AI 买家稀缺且关键的资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据可能存储在本地化的工业控制系统 (ICS) 和质量管理系统 (QMS) 中；严格的医疗器械法规 (ISO 13485) 确保高数据完整性和文档标准 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Encaplast 拥有一个专有数据集，其中详细说明了医疗器械包装的技术文档和合规性记录。这些高稀有度的文本数据是 RegTech 和合规性 AI 供应商用于构建复杂的监管 RAG模型的首选资产。在全球监管事务市场预计达到 164 亿美元的背景下，该数据集通过使 AI 能够应对复杂的灭菌和材料可追溯性要求，提供了独特的竞争优势。
See dimension details ↓- Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Legal Accessibility50
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility44
低难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity78
主导“监管”，行业医疗保健，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 次证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI 买家需求旺盛，这得益于在不断增长的 164 亿美元监管事务市场中实现合规性自动化的需求，该市场预计复合年增长率为 8.8%。
How strongly AI builders and companies are likely to want this data, based on market signals. - Right to License92
所有权=公司所有，许可=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Encaplast 是一个良好目标，因为它是运营型中小企业，其核心业务是为医疗和制药行业制造专业包装，而不是销售数据，并且监管和生产流程可能产生有价值的、休眠的数据作为副产品。问题：员工人数因不同来源而异，从 17 到 99 人不等，但 2023 年的一篇文章称他们有 90 名员工，证实了其中小企业地位。
- Deep Qualification90
✓ 通过 — Encaplast 在严格的 ISO 13485 质量标准下为医疗和制药行业制造定制包装，这使得监管记录数据集作为其核心业务的副产品具有高度可信度。然而，由于缺乏公开的法律文件，数据所有权和许可权仍未得到确认。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据指向来自制造过程的时间序列数据，通过持续的环境和机器性能监控证明符合ISO 标准，这对于质量保证和监管审计至关重要。
Regulatory records
这些核心文本证据证实了医疗器械包装的全面技术文档的存在，包括 RegTech 公司为培训合规模型所寻求的关键灭菌兼容性和可追溯性数据。
business_records
这些文件证据揭示了包装所用特定材料的详细技术规格和性能数据，这是验证材料选择是否符合监管要求的宝贵资源。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Encaplast Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Affairs Market = $16.4 billion in 2024, CAGR 8.8% (source: Grand View Research). Investment score 68.6/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Erea Ingenierie — 监管记录数据集机会
View opportunity →出行Ritra — 监管记录数据集机会
View opportunity →工业Plastixglobal — 监管记录数据集机会
View opportunity →